Technical Analysis for INBX - Inhibrx, Inc.

Grade Last Price % Change Price Change
D 34.94 -0.17% -0.06
INBX closed down 0.17 percent on Monday, March 18, 2024, on 69 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -0.17%
Oversold Stochastic Weakness -0.17%
Oversold Stochastic Weakness -0.14%
Narrow Range Bar Range Contraction -1.16%
Oversold Stochastic Weakness -1.16%
Narrow Range Bar Range Contraction -0.85%
Doji - Bullish? Reversal -0.85%
Stochastic Reached Oversold Weakness -0.85%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 11 hours ago
Possible Inside Day about 11 hours ago
Fell Below Previous Day's Low 4 days ago
Down 1% 5 days ago
Fell Below Previous Day's Low 5 days ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Inhibrx, Inc. Description

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc-fusion protein-based therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency; and INBRX-103, a mAb in Phase 1 clinical trials that targets cluster of differentiation 47. Its preclinical programs include INBRX-106, a sdAb-based hexavalent agonist of OX40 for a range of oncology indications; and INBRX-111, a multi-functional antibody that targets Pseudomonas aeruginosa. The company was founded in 2010 and is headquartered in La Jolla, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Solid Tumors Tumor Clinical Research Clinical Trial Sarcoma Antitrypsin Deficiency Fusion Protein Pseudomonas Clusters Of Differentiation Pseudomonas Aeruginosa

Is INBX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 39.79
52 Week Low 14.305
Average Volume 783,687
200-Day Moving Average 25.76
50-Day Moving Average 36.63
20-Day Moving Average 36.51
10-Day Moving Average 35.33
Average True Range 0.84
RSI (14) 38.27
ADX 24.68
+DI 16.72
-DI 27.75
Chandelier Exit (Long, 3 ATRs) 37.26
Chandelier Exit (Short, 3 ATRs) 36.78
Upper Bollinger Bands 39.40
Lower Bollinger Band 33.62
Percent B (%b) 0.23
BandWidth 15.85
MACD Line -0.49
MACD Signal Line -0.25
MACD Histogram -0.248
Fundamentals Value
Market Cap 1.66 Billion
Num Shares 47.4 Million
EPS -4.25
Price-to-Earnings (P/E) Ratio -8.22
Price-to-Sales 4065.90
Price-to-Book 13.69
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 35.42
Resistance 3 (R3) 35.46 35.34 35.34
Resistance 2 (R2) 35.34 35.22 35.32 35.31
Resistance 1 (R1) 35.14 35.14 35.08 35.10 35.29
Pivot Point 35.02 35.02 34.99 35.00 35.02
Support 1 (S1) 34.82 34.90 34.76 34.78 34.59
Support 2 (S2) 34.70 34.82 34.68 34.57
Support 3 (S3) 34.50 34.70 34.54
Support 4 (S4) 34.46